Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinitech LaboratoryBOM:544220 -7.50%38 PEG Ratio is 5.03 as of Aug. 23, 2026, which is 8% below its 10-year median of 5.49. GuruFocus rates BOM:544220 with a GF Score™ of 38/100. The stock has 6 warning signs investors should review. Among 37 Medical Diagnostics & Research companies, Clinitech Laboratory ranks worse than 75.68% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Clinitech Laboratory's PEG Ratio or its related term are showing as below:
BOM:544220'
s PEG Ratio Range Over the Past 10 Years
Min: 4.81 Med: 5.49 Max: 6.25
Current: 5.03
During the past 6 years, Clinitech Laboratory's highest PEG Ratio was 6.25. The lowest was 4.81. And the median was 5.49.
BOM:544220's PEG Ratio is ranked worse than 75.68% of 37
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.74
vs BOM:544220: 5.03
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Clinitech Laboratory (BOM:544220) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Clinitech Laboratory PEG Ratio Related Terms
Clinitech Laboratory PEG Ratio Historical Data
* Premium members only.
The historical data trend for Clinitech Laboratory's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544220 vs TMO, DHR, IDXX: PEG Ratio Comparison
For the Diagnostics & Research subindustry, Clinitech Laboratory's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinitech Laboratory PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinitech Laboratory's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Clinitech Laboratory's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Clinitech Laboratory (BOM:544220) has a PEG Ratio of 5.03 as of Aug. 23, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Clinitech Laboratory and its competitors. This is near median its historical median of 5.49. Over the past decade, Clinitech Laboratory's PEG Ratio has ranged from 4.81 to 6.25. According to the industry distribution chart, Clinitech Laboratory ranks #28 out of 37 companies in the Medical Diagnostics & Research industry, placing it in the top 75.7%.
Is Clinitech Laboratory's PEG Ratio too high?
Clinitech Laboratory's current PEG Ratio of 5.03 is near median its 10-year median of 5.49. Over the past 10 years, this metric has ranged from a low of 4.81 to a high of 6.25. The Medical Diagnostics & Research industry median PEG Ratio is 2.74. Clinitech Laboratory's value of 5.03 is 83.6% above this industry median. Based on the distribution chart, Clinitech Laboratory ranks #28 out of 37 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Clinitech Laboratory has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Clinitech Laboratory's PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinitech Laboratory ranks #28 out of 37 companies for PEG Ratio. This places Clinitech Laboratory in the lower half of its industry. The industry median PEG Ratio is 2.74. Clinitech Laboratory's value of 5.03 is 83.6% above this benchmark. Historically, Clinitech Laboratory's own PEG Ratio has ranged from 4.81 to 6.25 over the past decade. While the company's 10-year median is 5.49 vs. the industry median of 2.74, Clinitech Laboratory has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.74, based on 37 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinitech Laboratory's current PEG Ratio of 5.03 is 83.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Clinitech Laboratory and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinitech Laboratory's current PEG Ratio is 5.03, which is near median its own 10-year median of 5.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinitech Laboratory stock overvalued right now?
Clinitech Laboratory (BOM:544220) has a current PEG Ratio of 5.03. The current PEG Ratio is 5.03, which is near median its 10-year median of 5.49 and 83.6% above the Medical Diagnostics & Research industry median of 2.74. Clinitech Laboratory's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Clinitech Laboratory (BOM:544220), the current PEG Ratio is 5.03 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clinitech Laboratory Ltd is an Indian diagnostic and healthcare services provider company. It operates a network of diagnostic centers in Thane and Navi Mumbai and offers various medical tests across multiple specialties, including biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology. It serves individual patients as well as corporate clients, aiming to provide affordable and comprehensive diagnostic solutions.
38GF Score
Get the complete analysis for BOM:544220
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544220 has been successfully added to your 
